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A potential post-antibiotic era is threatening present and future medical 
advances. The current worldwide increase in resistant bacteria and, 
simultaneously, the downward trend in the development of new antibiotics have 
serious implications. This research conducted to study the resistance profile of 
bacterial isolates from wastewater samples effluent from Al-Shifa hospital in 
Gaza as a health institution and comparing their profile with bacteria isolated 
from wastewater samples effluent from anon-health institution. In this study, 
wastewater sample were collected from three different sewers receiving 
wastewater in Al-Shifa hospital, from three sewers receiving wastewater in 
Islamic university of Gaza (IUG), from inlet and outlet of Gaza wastewater 
treatment plant (WWTP) and from seawater. A total of 45 samples were 
collected and the total number of different bacterial species that was isolated 
was 154 different bacteria. From the isolated bacteria 30.5% E. coli, 33.1% 
Pseudomonas spp., 10.4% Klebsiella spp., 4.5% Proteus spp. and 21.4% 
Enterococcus spp. Isolates were subjected to antimicrobial susceptibility testing. 
the percent of resistance for Gram-negative bacteria to 15 antibiotics were as 
the following Cephalexin (52.1%), Co-Trimoxazole (41.3%), Tetracycline 
(41.3%), Chloramphenicol (39.7%), Nalidixic Acid (36.4%), Piperacillin (28.9%), 
Amoxycillin (35.5%), Ceftizoxime (14.0%), Azreonam (13.2%), Ciprofloxacin 
(12.4%), Tobramycin (11.6%), Gentamicin (10.7%), Ceftazidime and Amikacin 
(8.3%) and Imipenem (0.0%). The percent of resistance for Gram-positive 
bacteria (Enterococcus) to 5 antibiotics were as the following: Streptomycin 
(91.0%), Vancomycin (75.8%), Erythromycin (60.6%), Teicoplanin (9.1%) and 
Ampicillin (6.1%).   
In conclusion we demonstrated that bacteria isolates from wastewater samples 
from Al-Shifa hospital and Laboratory building of IUG had higher number of 






 حیوی ة تلمضادات الحیویة باإلضافة لالنحدار ف ي اتج اه تط ویر م ضادا ل  البكتیریا مقاومةالزیادة العامة لمشكلة إن 
 ع ن  طری ق  لقد صمم ھذا البحث لدراسة صور مقاومة البكتیری ا للم ضادات الحیوی ة و.مضاعفات خطیرة جدیدة لھ 
 مست شفى ال شفاء ف ي قط اع غ زة كمؤس سة ص حیة ومقارن ة جة م ن  المیاه العادمة الخار البكتیریا من أنواع من عزل 
ف ي ھ ذه الدراس ة جمع ت .  مؤس سات غی ر ص حیة  میاه عادمة خارجة منصور المقاومة ھذه مع بكتیریا عزلت من 
 ف ي اإلس المیة  م ن الجامع ة  أم اكن مختلف ة  مختلفة من مستشفى ال شفاء وث الث أماكنعینات المیاه العادمة من ثالث 
 م ن م صب محط ة ب ب القر البح ر ومن مدخل ومخرج محطة غزة لمعالجة المیاه العادمة وعینة من میاه قطاع غزة 
 ت م  ك ان مجم وع البكتیری ا المختلف ة الت ي  عین ة وق د 45مجم وع العین ات الت ي ت م جمعھ ا ك ان .  في البحر ةالمعالج
  :لي نسب البكتیریا المعزولة كالتاتوكان.  من ھذه العینات بكتیریا154 ھاعزل
30.5% E. coli, 33.1% Pseudomonas spp., 10.4% Klebsiella spp., 4.5% Proteus 
spp. and 21.4% Enterococcus spp.   
وكان ت ن سبة مقاوم ة البكتیری ا ال سالبة الج رام . البكتیریا المعزولة اجري لھ ا اختب ار  الح ساسیة للم ضادات الحیوی ة 
  :ليلخمسة عشر مضادا حیویا على النحو التا
 Cephalexin (52.1%), Co-Trimoxazole (41.3%), Tetracycline (41.3%), 
Chloramphenicol (39.7%), Nalidixic Acid (36.4%), Piperacillin (28.9%), 
Amoxycillin (35.5%), Ceftizoxime (14.0%), Azreonam (13.2%), Ciprofloxacin 
(12.4%), Tobramycin (11.6%), Gentamicin (10.7%), Ceftazidime and Amikacin 
(8.3%) and Imipenem (0.0%).  
  :ونسبة مقاومة البكتیریا الموجبة الجرام لخمس مضادات حیویة على النحو التالي
 Streptomycin (91.0%), Vancomycin (75.8%), Erythromycin (60.6%), 
Teicoplanin (9.1%) and Ampicillin (6.1%).   
ن البكتیریا المعزولة من عینات المی اه العادم ة الخارج ة م ن مست شفى ال شفاء وم ن مبن ى المختب رات ف ي ولقد وجد أ 
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In the past, bacteria were the most important cause of disease and mortality 
among humans. The introduction of antibiotics in human medicine has markedly 
reduced the impact of bacterial diseases on human mortality (1). In the past 50 
years, antibiotics have been critical in the fight against many diseases and 
infections. Their discovery was one of the leading causes for the dramatic rise of 
average life expectancy in the 20th century and their significance to public health 
would be impossible to overstate. Antibiotics are defined as any compound which 
either kills or severely impedes the growth of bacteria (2). 
 
Before the discovery of the first antibiotic, penicillin, in 1928, infections that are 
easily treated today killed millions of people around the world (3). These gains are 
now seriously jeopardized by another recent development: the emergence and 
spread of microbes that are resistant to cheap and effective first-choice or "first-
line" drugs (4). 
 
The first case of penicillin resistance in E. coli was reported in the 1950,s (1).  
Since then, things have taken a turn for the worse. Today, antibiotic resistance 
represents an important problem in the therapy of various human pathogenic 
bacteria. Three bacterial species causing life-threatening infections (Pseudomonas 
aeruginosa, Mycobacterium tuberculosis and Enterococcus faecalis) can 
demonstrate resistance to any available antibiotic. Vancomycin is the only effective 
drug for the treatment of infections caused by methicillin-resistant Staphylococcus 
aureus (MRSA), but the occurrence of strains with reduced susceptibility to this 
antibiotic has already been reported. Problems may also occur in the therapy of 
hospital infections caused by Acinetobacter Baumannii, Haemophilus influenzae, 
Klebsiella pneumoniae, Neisseria meningitidis and Streptococcus pneumoniae (1). 
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The problem of antibiotic resistance is of particular concern for immunosuppressed 
patients, such those affected by HIV, cancer or chronic diseases, as antibiotic 
therapy represents the only way to overcome bacterial infection for these people. 
Serious problems may also occur in developing countries where the use of new 
and expensive drugs is limited by their cost and availability. In addition to the risks 
for human health, this situation incurs a worldwide increase in the cost of hospital 
care, including the use of new expensive drugs, increased costs for bacteriological 
analysis and prolonged hospitalization (5). 
 
Antibiotic resistance has become a major clinical and public health problem within 
the lifetime of most people living today (6). Confronted by increasing amounts of 
antibiotics over the past 60 years, bacteria have responded to the deluge with the 
propagation of progeny no longer susceptible to them. While it is clear that 
antibiotics are pivotal in the selection of bacterial resistance, the spread of 
resistance genes and of resistant bacteria also contributes to the problem (6). 
 
An important feature contributing to the dissemination of antibiotic resistance is the 
ability of the resistance genes to move into other bacteria by a variety of genetic 
means. The microbial environment has carried these various gene distribution 
systems over evolutionary periods, using them to defend itself against threats to its 
existence, such as those posed by antibiotics (6). 
 
Antibiotic resistance is not only found in pathogenic bacteria but also in 
environmental organisms inhabiting terrestrial and aquatic habitats. However, 
higher numbers of resistant bacteria occur in polluted habitats compared with 
unpolluted habitats, indicating that humans have contributed substantially to the 
increased proportion of resistant bacteria occurring in the environment (7, 8). 
 
The emergence and spread of antimicrobial resistance are complex problems 
driven by numerous interconnected factors (4). The widespread and often 
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inappropriate administration of antibiotics in livestock, pets, and humans has been 
shown to result in the development of antibiotic-resistant bacteria and is generally 
accepted to be the primary pathway for proliferation of antibiotic-resistant bacteria 
in the environment (9). 
 
Possible mechanisms by which humans enhance the spread of antibiotic 
resistance among environmental bacteria include the deliberate or accidental 
introduction of antibiotics, resistant bacteria and resistance genes into the 
environment. Antibiotics exert a selection in favor of resistant bacteria by killing or 
inhibiting growth of susceptible bacteria; resistant bacteria can adapt to 
environmental conditions and serve as vectors for the spread of antibiotic 
resistance (9, 10). 
 
The main risk for public health is that resistance genes are transferred from 
environmental bacteria to human pathogen (9, 10). There are several routes of 
entry of antimicrobial agents into the environment. Studies have shown that 
introduction by these routes has changed the antibiotic susceptibility of the 
microbes in those environments (11). 
 
One of these route is the sewage, the antibiotics that we take in are not all 
processed by our bodies. Some of them are expelled as waste and wind up in our 
wastewater treatment plants. Of bacteria isolated from sludge remaining after 
wastewater treatment at one plant, 46.4% were resistant to multiple antibiotics. 
Sewage from hospitals and pharmaceutical plants has been shown to contribute to 
antibiotic resistance in treatment plants (11). 
 
The volume of antibiotics used in hospitals and private households and released 
into effluent and municipal sewage indicates a selection pressure on bacteria (12). 
Waste effluent from hospitals contains high numbers of resistant bacteria and 
antibiotic residues at concentrations able to inhibit the growth of susceptible 
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bacteria (13,14,15). Accordingly, hospital waste effluent could increase the 
numbers of resistant bacteria in the recipient sewers by both mechanisms of 
introduction and selection for resistant bacteria (16). 
 
1.2 Aim of the study 
 
Bacteria in waste effluents from hospital are exposed to high levels of various 
chemicals including antimicrobials that are disposed into wastewater systems. 
Antimicrobials may exert selective pressure on bacteria leading to the elimination 
of sensitive strains and allowing resistant ones. Resistant bacteria can transfer 
their resistance characteristics to other bacteria in the surrounding environments 
through several mechanisms.  Al-Shifa hospital is one of the largest hospitals in the 
Gaza Strip. It discharges sewage into the sewage system connected to the Gaza 
Wastewater Treatment Plant. Along the way to the GWWTP, it combines with 
sewage from local community. The efficiency of the GWWTP is believed by many 
to be low and in several documented occasions discharged untreated wastewater 
directly to the sea. This poses a serious public health threat to the locals because 
of the fact that sewage contains pathogenic microorganisms and the threat 
becomes more and more real if these pathogens are originating from hospital or 
has the opportunity to acquire resistance through contact with resistant hospital 
pathogens. 
 
This research aims at studying the resistance profile of bacterial isolates from Al-
Shifa hospital as a health institution and comparing their profile to a non-health 
institution. The following specific objectives were achieved: 
 
• The pattern of antibiotic resistance of five bacterial strains (E. coli, 
Pseudomonas spp., Proteus spp., Klebsiella spp., and Enteroccocus spp.) 
isolated from the sewage of Al-Shifa hospital in comparison to the same 
isolates from the sewage of Islamic University of Gaza. 
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• The contribution of resistant strains by the different wards in the hospital. 
 
• Study the pattern of resistance of the same five bacterial strains isolated 
from Gaza Wastewater Treatment Plant (GWWTP) and the effect of 




Antimicrobial resistance is driving up health care costs, increasing the severity of 
disease, and increasing the death rates from certain infection. Human activities 
other than indiscriminate use of antibiotics in human medicine, animal husbandry 
and agriculture, and inappropriate wastewater treatment and disposal may disrupt 
the microbial balance in favor of resistant bacteria. This study would highlight and 
demonstrate the extent of hospital effluents contribution to the resistance 
phenomena in Gaza. Thus providing data for policy makers and local authorities, 
this may assist in future planning in an attempt to reduce antibiotic resistance and 
associated burdens.  
 
There are numerous studies that are concerned with applying antibiotic profiles in 
tracing source of bacterial contamination. This trend was tested during the course 










2.1.1 Definition of an antibiotic 
 
Antibiotics are substances produced by living organisms, which are able to kill 
or inhibit the growth of other microorganisms (17). Antibiotics are product of the 
earth, more specifically of soil; they are byproducts of cellular metabolisms; 
antibiotics are "all natural" (18). According to the literal sense of the word, 
substances produced synthetically (e.g. sulfonamides or quinolones) should not 
be termed antibiotics, and the use of broader term (i.e. Antimicrobial agents) 
would be more appropriate to indicate the complex of all substances having a 
harmful effect on microorganisms (17). However, the term antibiotic is used 
throughout the present thesis as a synonym of antimicrobial agents. 
 
2.1.2 History of antibiotic development 
Interest in antimicrobial chemotherapy was kindled as soon as microorganisms 
were understood to be agents of infectious disease. In earlier times, plant 
products were sometimes used successfully in the treatment of disease, but 
neither doctors nor patients know the basis for the action of these therapeutic 
agents. Many early medicines were used to cure protozoan diseases, rather 
than bacterial diseases. As early as 1619, it was known that malaria could be 
treated with the extract of cinchona bark (quinine) and that amoebic dysentery 
could be treated with ipecacuanha root (emetine) (19,20). Only a few 
antibacterials, such as mercury, which was used to treat syphilis, were in use 
when the era of true chemotherapy began. 
 
It was in the early 1900's when Paul Ehrlich first hypothesized that dyes could 
be used as antimicrobial drugs, based on their differential affinities for various 
tissues. In 1904, Ehrlich and Shiga discovered that a red dye called trypanrot 
was effective against trypanosomes (21). It was around this time that  
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arsenicals drew Ehrlich's interest. Ehrlich, along with Sahachiro Hata in 1909, 
found that arsphenamine (named Salvarsan) was active against spirochetes 
and, therefore, was an effective cure for syphilis (19). 
 
The seminal work of Joseph Lister, Louis Pasteur, Robert Koch, and others-
identifying microbes as agents of disease and devising means for avoiding 
infections by the use of disinfectants and antiseptics-made possible rational 
approaches to the treatment of infectious diseases (22).  
 
True antimicrobial therapy became available only in the 1930s with the 
discovery of the sulfonamides by Gerhardt Domagk (22). Gerhard Domagk, a 
German doctor, announced the discovery of a synthetic molecule with 
antibacterial properties (2). In 1932, two scientists at the Bayer company, 
Mietzsch and Klarer, synthesized Prontosil red, a red dye bound to a 
sulfonamide group. Domagk (23) showed, in 1935, that infections in mice 
caused by hemolytic streptococci were cured by Prontosil red (19, 20).  
 
Unfortunately for Bayer, Prontosil red was shown to have no antibacterial 
activity in vitro. This lack of activity was explained by Trefouel et al. (24) when 
they showed that Prontosil red is split in vivo into its component dye and 
sulfanilamide, the active antibacterial agent and a previously described 
molecule that was already in the public domain. From that point, sulfanilamide 
was manufactured by a number of companies and work was begun to modify 
the molecule to enhance performance, leading to decreased side effects and a 
broader spectrum of action (20). 
 
Although penicillin was the first natural antibiotic to be discovered, the idea of 
using microorganisms therapeutically was not new. Fungi had been used in 
poultices for many years, and by 1899, a product called pyocyanase, which was 




In 1928, Alexander Fleming was searching for potential antibacterial 
compounds. He noticed that a patch of the mould Penicillium notatum had 
grown on a plate containing the bacteria Staphylococcus and that around the 
mould there was a zone where no Staphylococcus could grow. After more 
research, he was able to show that culture broth of the mold prevented growth 
of the Staphylococcus even when diluted up to 800 times. He named the active 
substance penicillin but was unable to stably isolate it. Several years later, in 
1939, Ernst Chain and Howard Florey developed a way to isolate penicillin and 
used it to treat bacterial infections during the Second World War (2). By 1941, 
Ernst Chain, Howard Florey, and Norman Heatley had shown the therapeutic 
value of penicillin (25), but they were also unable to produce enough penicillin 
for commercial use. Collaboration with Andrew Moyer and Robert Coghill (26) at 
the USDA's Northern Regional Research Laboratory in Illinois led to much 
higher production yields of penicillin by 1943. After a worldwide search for 
Penicillium strains that could produce more penicillin, Raper and Fennel (27) 
found a strain of Penicillium chrysogenum on a moldy cantaloupe at a local 
market that was capable of even higher yields of penicillin (28). The new drug 
came into clinical circulation in 1944 and made a huge impact on public health. 
For these discoveries Fleming, Chain and Florey were awarded the Nobel Prize 
for Medicine in 1945. Their discovery and development revolutionized modern 
medicine and paved the way for the development of many more natural 
antibiotics (2). 
The discovery of penicillin stimulated search for antibiotics in many parts of the 
world and numerous substances were discovered, products of various kinds of 
moulds, bacteria, or plants which would kill other bacteria. But the great majority 
of these were unsuitable for medical use. They were either too poisonous or too 
difficult to purify or liable to degenerate on keeping; or, for some reason or 
other, they failed to meet the special requirements needed for a 
chemotherapeutic drug. Researchers began to feel that perhaps penicillin was 
unique in the field of antibiotics. It certainly is a remarkable coincidence that the 
first antibiotic to be tested at all thoroughly proved such a wonderful drug, 
whereas hundreds which were subsequently tested proved duds (29).  
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In 1940, Selman Waksman began searching for antibiotic compounds produced 
by soil microorganisms (19). In 1943, one of Waksman's students discovered 
streptomycin (30), leading to a flood of researchers combing the world for new 
drugs. It was in this same period that Rene Dubos (31) discovered gramicidin, 
the first antibiotic active against gram-positive bacteria. Chlortetracycline, 
chloramphenicol, and others were discovered shortly thereafter (20). Many 
discoveries were of drugs that were too toxic for human use, or that had already 
been discovered. Nevertheless, this work did lead to many new drugs and 
within only 10 years, drugs comprising the major classes of antibiotics were 
found (19). In addition to soil, many of these drugs were discovered by isolating 
the producing microorganisms from interesting and unusual sources. For 
example, some antibiotic-producing bacteria were isolated from a wound 




In 1962, one of the later discoveries was a synthetic drug, nalidixic acid, the first 
of the quinolones to be described, and although not therapeutically important by 
itself, modification of nalidixic acid led to the production of the highly effective 
fluoroquinolones. Members of this class, such as ciprofloxacin, norfloxacin, 
enrofloxacin, and ofloxacin, have become very important in the treatment of 
diseases in both humans and animals (21). Since the 1960's,  there have been 
few discoveries of new antibiotic drugs. The drugs developed since have mostly 
been chemical modifications of existing drugs. These modifications have been 
very useful in treating infectious diseases, leading to enhanced killing of 
pathogens, increased spectrum of action, reduced toxicity, and reduced side 
effects. Unfortunately, since the 1970's, only one new class of antibiotics has 
been introduced (32) and a recent trend in antibiotic therapy has been to 
employ combinations of drugs with different mechanisms of action, in order to 





Antibiotics are classified based on their chemical structure. Each class of 
antibiotics is characterized by a typical core structure and the various members 
of the class are differentiated by the addition or subtraction of secondary 
chemical structures from the core structure. The main classes of antibiotics 
currently used in clinical practice include penicillins, cephalosporins, 
tetracyclines, aminoglycosides, fluoroquinolones, potentiated sulfonamides, 
macrolides and glycopeptides (16). Antibiotics can also be classified as broad, 
intermediate or narrow spectrum, depending on the range of bacterial species 
against which they are active (16). 
 
2.1.4 Mechanisms of action 
Antibiotics constitute quite a heterogeneous group of chemicals. Depending on 
the chemical structure, antibiotics exert an effect on different structures or 
functions of the bacterial cell. The major mechanisms of action are inhibition of 
the cell wall synthesis, damage of the cell membrane function, inhibition of 
protein synthesis, inhibition of the nucleic acid synthesis, and metabolic 
antagonism (16). 
 
2.1.4.1 Inhibition of cell wall synthesis 
There are two major groups of cell wall synthesis inhibitors, the β-lactams and 
the glycopeptides. As bacterial cell walls are wholly unlike the membranes of 
eukaryotes, they are an obvious target for selectively toxic antibiotics. The β-
lactams include the penicillins, cephalosporins, and the carbapenems. These 
agents bind to the penicillin binding proteins (PBP's) that cross-link strands of  
peptidoglycan in the cell wall. In gram negative cells, this leads to the formation 
of fragile spheroplasts that are easily ruptured. In gram positive cells, autolysis 
is triggered by the release of lipoteichoic acid (19). 
 
The mechanism of β -lactam resistance is via the action of the β -lactamases. 
These enzymes catalyze hydrolysis of the β-lactam ring and, thereby, inactivate 
these antibiotics. Many bacteria contain chromosomally encoded β-lactamases 
 11
necessary for cell wall production and it is only through over-production of these 
enzymes that resistance occurs (19). β-lactamases encoded on plasmids or 
other transmissible elements can lead to such overproduction and, therefore, to 
resistance (33). There are also some bacteria that possess altered PBP's that 
result in reduced penicillin binding (19). 
 
Since the discovery of penicillin and resistant bacteria, various new versions of 
the β -lactams have been used that have different spectrums of activity and 
different susceptibility to β-lactamases. Since the 1970s, several compounds, 
such as clavulanic acid, have been discovered that have the ability to bind 
irreversibly to β-lactamases and, thereby, inhibit their action. Combinations of 
these compounds with β-lactam drugs have been very successful in treatment 
of disease (34). 
 
The glycopeptides are a group of antibiotics that include vancomycin, 
avoparcin, and others that bind to acyl-D-alanyl-D-alanine. Binding of this 
compound prevents the addition of new subunits to the growing peptidoglycan 
cell wall. These drugs are large molecules that are excluded from gram 
negative cells by the outer membrane, thus limiting their action to gram positive 
organisms. 
 
Glycopeptide resistance was long thought to be rare, but has recently been 
shown to be quite common (34). Resistance in enterococci has developed 
through newly discovered enzymes that use D-alanyl-D-lactate in place of acyl-
D-alanyl-D-alanine, allowing cell wall synthesis to continue. Other mechanisms 
of resistance involve the over-production of peptidoglycan precursors which 
overwhelm the drug (19). 
 
2.1.4.2 Inhibitors of protein synthesis 
There are many types of antibiotics that inhibit bacterial protein synthesis. 
These drugs take advantage of structural differences between bacterial 
ribosomes and eukaryotic ribosomes. 
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The aminoglycoside antibiotics are a group whose mechanism of action is not 
completely understood. The three major groups of aminoglycosides are the 
streptomycins, neomycins, and kanamycins. These drugs enter bacterial cells 
by an active transport that involves quinones that are absent in  anaerobes and 
streptococci, thus excluding these organisms from the  spectrum of action. 
Streptomycins act by binding to the 30S ribosomal subunit. Kanamycins and 
neomycins bind to both the 50S subunit and to a site on the 30S subunit 
different from that of streptomycin (19). Activity involving initiation complexes 
and cell membrane proteins that contribute to cell death plays a role in the 
action of these antibiotics, but this is poorly understood (19, 34). 
 
There are three mechanisms of aminoglycoside resistance that have been 
identified to date. The first involves only streptomycin. Since streptomycin binds 
to one particular protein on the ribosome, alteration of this protein, even by a 
single amino acid in its structure, confers high-level resistance to the drug (34). 
The other mechanisms involve decreased uptake of the antibiotic and in one of 
these the cell membrane is altered, preventing active transport of the drug. In 
the other, one of many enzymes alters the antibiotic as it enters the cell, 
causing a block in further active transport (34). 
 
Chloramphenicol is a broad-spectrum antibiotic that, although naturally 
occurring, is produced by chemical synthesis. Chloramphenicol inhibits peptide 
bond formation on 70S ribosomes (34). This drug is especially useful in that it 
can penetrate eukaryotic cells and cerebrospinal fluid, making it a drug of 
choice for treatment of meningitis and intracellular bacterial infections such as 
those caused by Chlamydia. It is not in widespread use, however, because of 
potentially fatal side-effects, namely,  aplastic anemia (19). 
 
Resistance to Chloramphenicol is conferred by the enzyme Chloramphenicol 
acetyl-transferase. A number of these enzymes have been discovered, each 
altering the Chloramphenicol molecule to prevent binding to the bacterial 
ribosome. Chloramphenicol resistance in gram negative cells can also arise 
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from alteration in outer membrane permeability that prevents the drug from 
entering the cell (34). 
 
The tetracyclines are another group of broad-spectrum antibiotics that inhibit 
bacterial protein synthesis. They are brought into the cell by active transport 
and, once there, bind to the 30S subunit to prevent binding of aminoacyl tRNA 
(35). 
 
Resistance to the tetracyclines occurs via three mechanisms. First, production 
of a membrane efflux pump which remove the drug as rapidly as it enters and 
there are several genes encoding these pumps. Second, several ribosome 
protection proteins act to prevent tetracycline from binding to the ribosome, thus 
conferring resistance. Third, a protein found only in Bacteroides spp., 
enzymatically inactivates tetracycline (35). Interestingly, efflux pump inhibitors 
have recently been discovered that may allow combinations of these inhibitors 
and tetracyclines to be used against previously resistant strains (36). 
 
The macrolides are a group of antibiotics commonly used to treat gram positive 
and intracellular bacterial pathogens. Erythromycin was the first of these, and 
several other important macrolides have been discovered since, including 
clarithromycin and azithromycin. Azithromycin has a longer plasma half-life 
which allows treatment with a single dose for some pathogens or one daily dose 
for others. Clarithromycin has enhanced absorption and causes less 
gastrointestinal discomfort (37). It was originally believed that erythromycin 
inhibited protein synthesis by competing with amino acids for ribosomal binding 
sites, but newer research shows several mechanisms are involved (20). The 
macrolides are now believed to promote dissociation of tRNA from the 
ribosome, inhibit peptide bond formation, inhibit ribosome assembly, and 
prevent amino acid chain elongation (37). 
 
There are two major mechanisms of macrolides resistance. First, an efflux 
pump has been found that removes the drug from the cell. Second, modification 
 14
of the ribosome can confer resistance. Mutations at several sites of the 
ribosome can allosterically prevent macrolides binding and a common alteration 
is dimethylation of one nucleotide on the 23S rRNA. This dimethylation not only 
prevents macrolides binding, but also confers resistance to lincosamide and 
streptogramin antibiotics (37). 
 
The streptogramins are another class of antibiotic that inhibits bacterial protein 
synthesis, mostly in gram positive organisms (due to decreased permeability of 
the gram negative outer membrane). These antibiotics are actually 
combinations of structurally different drugs, types A and B, that act 
synergistically. These compounds bind to separate sites on the 50S subunit. 
Type A drugs block attachment of substrates at two sites on the 50S subunit, 
whereas type B drugs cause release of incomplete protein chains. The 
synergistic effect arises from a conformational change induced by the binding of   
type A drug which significantly increases affinity of type B drugs (38). 
Streptogramins currently in use include virginiamycin, pristinamycin, and 
quinupristin/dalfopristin. 
 
Resistance to streptogramin antibiotics can be found in several forms. Efflux 
pumps for both type A and B streptogramins have been identified. Type A 
streptogramins can be inactivated by one of the virginiamycin acetyl-
transferases, and several enzymes have been identified that can inactivate type 
B streptogramins. Alteration of bacterial ribosomal proteins or RNA can also 
confer resistance. A common mutation is the dimethylation of one nucleotide on 
the 23S rRNA, mentioned previously, that gives rise to resistance to type B 
drugs, as well as macrolides and lincosamides (38). 
 
2.1.4.3 Inhibitors of nucleic acid synthesis 
The sulfonamides and the diaminopyrimidines should be discussed together, in 
that both only indirectly inhibit nucleic acid synthesis by inhibiting folate 
synthesis. Folate is a coenzyme necessary for the synthesis of purines and 
pyrimidines. Although both types of drugs are useful on their own, they exhibit a 
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synergistic effect when combined. Sulfonamides are currently not used 
commonly in medicine, but the combination drug trimethoprim-sulfamethoxazole 
is sometimes used in the treatment of urinary tract infections. Sulfonamides 
serve as an analog of p-aminobenzoic acid. Therefore, they competitively inhibit 
an early step in folate synthesis. Diaminopyrimidines, of which trimethoprim is 
the most common, inhibit dihydrofolate reductase, the enzyme that catalyzes 
the final step in folate synthesis (19). 
 
There are several resistance mechanisms that microorganisms employ against 
each of the anti-folate drugs. For example, sulfonamides are rendered 
ineffective by over-production of p-aminobenzoic acid or production of an 
altered dihydropteroate synthetase. The substrate for dihydropteroate 
synthetase is p-aminobenzoic acid, and the altered form has a much lower 
affinity for sulfonamides than for p-aminobenzoic acid (39). Trimethoprim 
resistance can also result from several mechanisms, e.g., over-production of 
dihydrofolate reductase or production of an altered, drug-resistant form can lead 
to resistance (34). In addition, both drugs can be enzymatically inactivated, 
resulting in resistance (39). 
 
The quinolones are a chemically varied class of broad-spectrum antibiotics 
widely used to treat many diseases, including gonorrhea and anthrax. Drugs in 
this class include nalidixic acid, norfloxacin, and ciprofloxacin. These drugs are 
commonly used and, worldwide, more ciprofloxacin is consumed than any other 
antibacterial agent (40). Quinolones inhibit bacterial growth by acting on DNA 
gyrase and topoisomerase IV, which are necessary for correct functioning of 
supercoiled DNA (19). Although quinolones target both enzymes, in gram 
negative organisms the primary target is DNA gyrase and, in gram positive 
organisms, the primary target is topoisomerase IV (41). 
 
There are three main mechanisms of resistance to quinolones. Resistance to 
some quinolones occurs with decreased expression of membrane porins. 
Cross-resistance to other drugs requiring these porins for activity also results 
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from these changes. A second mechanism of resistance is expression of efflux 
pumps in both gram negative and gram positive organisms (42) and the third is 
alteration of the target enzymes. Several mutations have been described in both 
quinolone target proteins that result in reduced binding affinities (41). It is 
believed that high-level quinolone resistance is brought about by a series of 
successive mutations in the target genes, rather than a single mutation (42). 
 
2.1.5 Antibiotics used in this research 
Amoxicillin: is broad spectrum semisynthetic penicillin with antibacterial activity 
against certain gram negative and gram positive organisms.  It is in activated by 
penicillinases including those produced by Staphylococcus aureus, E. coli, 
Pseudomonas, Klebsiella, and Enterobacter (43). 
 
Amoxicillin is considered the drug of choice for the treatment of acute sinusitis, 
acute otitis media, and of acute exacerbations of chronic bronchitis. In these 
cases it is superior to ordinary penicillin. It is also suitable for the treatment of 
streptococcal pharyngitis (e.g. in children) (44). 
 
Amikacin: an aminogylcoside antibiotic a semisynthetic derivative of 
Kanamycin.   Amikacin has the same spectrum of activity as gentamicin and 
tobramycin, but it is less susceptible to enzymatic inactivation. This makes 
amikacin valuable in managing infections caused by gram-negative bacilli 
resistant to gentamicin and tobramycin.   Amikacin’s use can include coverage 
against some aerobic gram negative bacteria, which include E. coli, Klebsiella, 
Proteus, Pseudomonas, Salmonella, Enterobacter, Serratia and Mycoplasma. 
Used in serious gram-negative bacilliary infections, In Bacteremia or 
Septicemia, or bone and joint infections   
 
Aztreonam: is the only clinically available member of a unique class of beta-
lactam antibiotics called 'monobactams'. As such, it is structurally related to the 
other beta-lactams: penicillins, cephalosporins, and carbapenems (e.g. 
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imipenem, meropenem). Its spectrum of activity is specific to gram negative 
organisms, including Haemophilus influenzae and Pseudomonas aeruginosa.  
It has no anti-gram positive activity and therefore has no role in the treatment of 
Staphylococcus aureus (including MRSA) or Streptococcus pneumoniae (45). 
 
Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, 
Cephalosporin, Third Generation. Effective against a broad range of gram-
positive and gram-negative bacteria. It is effective against bacteria resistant to 
ampicillin and other cephalosporins. Ceftazidime may be indicated in an 
extremely wide variety of gram-positive and gram-negative infections of the 
respiratory tract, the skin, urinary and genital tracts, septicemia, the abdominal 
cavity, and the central nervous system. Ceftazidime inhibits one of the enzymes 
involved in the synthesis of the bacterial cell walls. 
 
Ceftizoxime: is Cephalosporin, Third Generation. Use to treat infections due to 
sensitive gram-positive and gram-negative bacteria. All third generation 
cephalosporins are more active against certain gram-negative bacteria than 
second generation but are less active against gram-positive bacteria, notably 
Staphylococcus aureus. 
 
Cephoxitin: is Cephalosporin, Second Generation. Broad spectrum antibiotic. 
Cephoxitin may be indicated in cases  of lower respiratory tract infections, 
urinary tract infections, gynecological infections, intra-abdominal infections, 
skin, bone and joint infections and septicemia. 
 
Chloramphenicol:  is a protein synthesis inhibitor, has a broad spectrum of 
activity but it exerts a bacteriostatic effect.  Chloramphenicol was originally 
discovered and purified from the fermentation of a Streptomyces, but currently it 
is produced entirely by chemical synthesis. Chloramphenicol inhibits the 
bacterial enzyme peptidyl transferase, thereby preventing the growth of the 
polypeptide chain during protein synthesis (46).   
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Ciprofloxacin: is the generic international name for the synthetic antibiotic 
belonging to a group called flouroquinalones. Ciprofloxacin is bactericidal and 
its mode of action depends on blocking of bacterial DNA replication by binding 
itself to an enzyme called DNA gyrase, which allows the untwisting required to 
replicate one DNA double helix into two. Notably the drug has 100 times higher 
affinity for bacterial DNA gyrase than for mammalian. Ciprofloxacin is a broad-
spectrum antibiotic that is active against both gram-positive and gram-negative 
bacteria (47). 
Co-Trimoxazole: is a combination of two drugs that act together:  Trimethoprim 
and Sulfamethoxazole (48). Cotrimoxazole is active against a broad spectrum 
of gram-negative and gram-positive bacteria, as well as Nocardia and 
Toxoplasma. This combination is used to treat gram-negative urinary tract 
infections, and is the agent of choice for Nocardia infections.  Cotrimoxazole is 
also used to treat and prevent Pneumocystis carinii and toxoplasma infection.   
 
Gentamicin: is an aminoglycoside antibiotic, exert its activity by binding 
bacterial ribosomes and preventing the initiation of protein synthesis. 
Gentamicin is broad spectrum antibiotic, effective against a broad range of 
gram-positive and gram-negative bacteria (46).  
 
Imipenem: is the first of a new class of beta-lactam antibiotics called 
carbapenems, related to the penicillin/cephalosporin family of antibiotics. The 
antibacterial spectrum of imipenem exceeds any antibiotic investigated to date 
and includes gram-positive, gram-negative, and anaerobic organisms. It has the 
ability to kill a wide variety of bacteria. It works by interfering with their ability to 
form cell walls, and therefore the bacteria break up and die. Not destroyed by 
most beta-lactamases including those that mediate resistance to cefuroxime, 
cefotaxime and ceftazidime. 
 
Nalidixic Acid: is a synthetic chemotherapeutic agent which has activity mainly 
against gram-negative bacteria. Nalidixic acid belongs to a group of compounds 
called quinolones. Nalidixic acid is a bactericidal agent that binds to the DNA 
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gyrase enzyme which is essential for DNA replication. Binding of the drug 
inhibits DNA gyrase activity. The main use of nalidixic acid is in treatment of 
lower urinary tract infections (UTI). The compound is unusual in that it is 
effective against several types of Gram-negative bacteria such as E. coli, 
Enterobacter aerogenes, K.pneumonia and proteus species which are common 
causes of UTI (46). 
 
Piperacillin: is a semisynthetic broad-spectrum penicillin. It works by interfering 
with their ability to form cell walls and therefore the bacteria break up and die. 
Piperacillin is active against certain groups of bacteria especially Pseudomonas 
aeruginosa. 
 
Tetracycline: is broad-spectrum antibiotic with a wide range of activity against 
both gram-positive and gram-negative of bacteria. 
 
Tobramycin:  is an “aminoglycoside” antibiotic used to treat infections caused 
by many different bacteria. It acts by binding to the ribosomal 30S subunit and 
to prevent it from joining to the 50S subunit during protein synthesis. It may has 
a bactericidal effect because this leads to cytoplasmic accumulation of 
dissociated 30S subunits, which is apparently lethal to the cell. 
 
Teicoplanin: is a narrow spectrum antibiotic,  belongs to a group of antibiotics 
called glycopeptides. Bacteria have an external cell wall that is reinforced by 
molecules called peptidoglycans. The cell wall is vital for protection against the 
normal environment of the body in which the bacteria live. Teicoplanin works by 
blocking the formation of these peptidoglycans. By doing this the walls of the 
bacteria become weak and this results in the death of the bacteria. Teicoplanin 
is used to treat serious infections caused by gram-positive bacteria in heart and 
blood (49).  
 
Vancomycin: is a narrow spectrum antibiotic, belongs to a group of antibiotics 
called glycopeptides. It works by inhibiting a step in cell wall synthesis. 
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Vancomycin is not effective against gram-negative bacteria because it cannot 
penetrate their outer membrane. However, it has become important in clinical 
usage for treatment of infections by strains of Staphylococcus aureus that are 
resistant to virtually all other antibiotics (46).  
 
Ampicillin: is broad spectrum semisynthetic penicillin with antibacterial activity 
against certain gram-negative and gram-positive organisms. It works by 
inhibiting a step in cell wall synthesis (46). 
 
 Erythromycin: it belongs to a group of antibiotics called macrolides , 
characterized by structure that contain large lactone rings linked through 
glycoside bonds with amino sugars. It acts by inhibiting bacterial protein 
synthesis. Erythromycin is active against most gram-positive bacteria, 
Neisseria, Legionella and Haemophilus (46).  
 
2. 2 Antibiotic resistance 
2.2.1 Definition 
Antibiotic resistance is a relative term. A bacterial strain can be defined resistant 
if it survives in the presence of higher antibiotic concentrations in comparison 
with phylogenetically related strains (50). Thus, antibiotic resistance is not a 
bacterial property that can be determined by studying a single strain, but only by 
comparison under identical conditions of two or more strains belonging to the 
same genus or species.  
 
The above-mentioned definition of antibiotic resistance refers to in vitro 
conditions. Under in vivo conditions, antibiotic resistance is a context dependent 
term as it depends on the location of the bacterium and the bioavailability of the 
drug. For example, bacteria are less susceptible to antibiotics when assembled 
in biofilms (complex communities of microorganisms embedded in a matrix of 
extracellular material) compared with the same organisms living separately (51). 
In aquatic environments, binding of the antibiotic molecule with ions or 
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substances present in sediment strongly reduces both the activity of the drug 
and its absorption in the fish intestine (52). 
2.2.2 History of antibiotic resistance 
There is evidence that although resistant microorganisms existed in nature 
before the use of antibiotics, such microorganisms were mostly absent from 
human flora (53). However, in the intervening years, antibiotic resistant 
microorganisms have become frighteningly common. Almost as soon as 
antibiotics were discovered, researchers began to find microorganisms resistant 
to the new drugs. Even by 1909, when Ehrlich first began to study dyes and 
arsenicals, he found drug resistant trypanosomes (19). Resistant strains of 
Staphylococcus aureus in hospitals grew from less than 1% incidence, when 
penicillin first came into use, to 14% in 1946, to 38% in 1947, to more than 90% 
today (19). Worldwide, ampicillin and penicillin resistance can be found together 
in more than 80% of S. aureus strains (53). After World War II, sulfonamides 
were widely used to treat Shigella infections in Japan, but by 1952, only 20% of 
isolates were susceptible. As the Japanese began to switch to tetracycline, 
chloramphenicol, and streptomycin, Shigella strains that were multiply-resistant 
quickly began to appear (54). Within 30 years of their discovery, sulfonamides 
ceased to be an effective treatment for meningococcal disease (53). In the 
years since, reports of resistance have grown increasingly common, and 
pathogens that are resistant to almost all antibiotics have been found. It has 
become painfully obvious that antibiotic resistance is reaching a crisis stage and 
some clinicians have even forecasted that we are facing a return to the 
devastating diseases of the pre-antibiotic era (32, 53, 55). 
 
2.2.3 Molecular mechanisms of antibiotic resistant 
Bacterial resistance to antibiotics can be caused by different molecular 
mechanisms. The most common mechanisms include: reduced drug uptake 
(e.g. membrane impermeability to cephalosporins); active drug efflux (e.g. 
tetracycline efflux pumps); drug deactivation (e.g. hydrolysis of penicillins by 
beta-lactamases), modification of the drug target (e.g. mutations of the DNA 
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gyrase leading to quinolones resistance); increased concentration of the drug 
target (e.g. increased folic acid production that counteracts the inhibition of such 
production by sulfonamides), or alternative pathways to elude the drug effect 
(e.g. synthesis of folic acid using an enzyme which is not affected by 
sulfonamides) (56). 
 
2.2.4 Natural and acquired resistance 
An important distinction should be made between natural and acquired    
resistance. Bacteria are termed naturally, intrinsically or constitutively resistant 
when resistance is due to characteristic features typical of the species. For 
example, Pseudomonas aeruginosa is naturally resistant to penicillins, due 
partly to the inability of the drug to diffuse through the outer membrane (57) and 
partly to the deactivation of the drug by chromosomally encoded enzymes (i.e. 
Beta lactamases) (58). 
 
In contrast, acquired resistance emerges in a bacterial population that was 
previously susceptible, because of modifications of the bacterial DNA caused by 
either chromosomal mutation and selection (sometimes referred to as  vertical 
evolution) (18) or horizontal gene transfer. Natural resistance results from a 
long process of genetic evolution, whereas, acquired resistance can arise within 
a short time (one or few generations) (56). 
Vertical evolution: A spontaneous mutation in the bacterial chromosome 
imparts resistance to a member of the bacterial population. In the selective 
environment of the antibiotic, the wild types (non mutants) are killed and the 
resistant mutant is allowed to grow and flourish. The mutation rate for most 
bacterial genes is approximately 10-8. This means that if a bacterial population 
doubles from 10 8 cells to 2 x 10 8 cells, there is likely to be a mutant present for 
any given gene. Since bacteria grow to reach population densities far in excess 
of 10 9 cells, such a mutant could develop from a single generation during 15 
minutes of growth.  
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Horizontal evolution is the acquisition of genes for resistance from another 
organism. For example, a streptomycete has a gene for resistance to 
streptomycin (its own antibiotic), but somehow that gene escapes and gets into 
E. coli or Shigella. Or, more likely, some bacterium develops genetic resistance 
through the process of mutation and selection and then donates these genes to 
some other bacterium through one of several processes for genetic exchange 
that exist in bacteria (18).  
Bacteria are able to exchange genes in nature by three processes: conjugation, 
transduction and transformation. Conjugation involves cell-to-cell contact as 
DNA crosses a sex pilus from donor to recipient. During transduction, a virus 
transfers the genes between mating bacteria. In transformation, DNA is 
acquired directly from the environment, having been released from another cell. 
Genetic recombination can follow the transfer of DNA from one cell to another 
leading to the emergence of a new genotype (recombinant). It is common for 
DNA to be transferred as plasmids between mating bacteria. Since bacteria 
usually develop their genes for drug resistance on plasmids (called resistance 
transfer factors or RTFs), they are able to spread drug resistance to other 
strains and species during genetic exchange processes (18).  
The combined effects of fast growth rates, high concentrations of cells, genetic 
processes of mutation and selection, and the ability to exchange genes, 
account for the extraordinary rates of adaptation and evolution that can be 
observed in the bacteria. For these reasons bacterial adaptation (resistance) to 
the antibiotic environment seems to take place very rapidly in evolutionary time: 
bacteria evolve fast (18).  
2.2.5 Impact of antibiotic resistance 
In the last decades, bacterial resistance to antibiotics has assumed an 
increasing importance with regard to its impact on both public health and 
ecology. Obviously, the primary problem is represented by the emergence of 
antibiotic resistance among bacteria pathogenic to humans and animals, which 
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makes difficult the treatment of some life-threatening infections. However, 
independent from the risks for human health, is the spread of antibiotic 
resistance and the problems raised in ecological nature. In fact, the introduction 
and selection of resistant bacteria in the environment can lead to structural 
changes in the composition of microbial communities, with possible deleterious 
effects on the balance of natural ecosystems (17). 
To combat the occurrence of resistant bacteria, pharmaceutical companies 
must constantly research, develop and test new antimicrobials in order to 
maintain a pool of effective drugs on the market. Five years ago, there were 
approximately 150 antibiotics available to the public with new drugs appearing 
every 8-10 years. This appears to be a substantial amount. However, these 
numbers are misleading as many of these drug targets are similar. Since the 
drug development process is very costly, pharmaceutical companies often 
concentrate on finding antimicrobials similar to the ones already found to reduce 
the risk of producing an unmarketable drug. This means that it is easy for 
microorganism to develop resistance to a similar drug to which it already has 
resistance. Past and current strategies to combat resistance are not effective 
(18). 
Today, antibiotic resistance represents an important problem in the therapy of 
various human pathogenic bacteria. Three bacterial species causing life-
threatening infections (Pseudomonas aeruginosa, Mycobacterium tuberculosis 
and Enterococcus faecalis) can demonstrate resistance to any available 
antibiotic (1). Vancomycin is the only effective drug for treatment of infections 
caused by methicillin-resistant Staphylococcus aureus (MRSA), but  
the occurrence of strains with reduced susceptibility to this antibiotic has 
already been reported (59). Problems may also occur in the therapy of hospital 
infections caused by Acinetobacter baumannii, Haemophilus influenzae, 
Klebsiella pneumoniae, Neisseria meningitidis and Streptococcus pneumoniae 
(1). 
The problem of antibiotic resistance is of particular concern for 
immunosuppressed patients, such as those affected by HIV, cancer or chronic 
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diseases, as antibiotic therapy represents the only way to overcome bacterial 
infections for these people. Serious problems may also occur in developing 
countries where the use of new and expensive drugs is limited by their cost and 
availability. In addition to the risks for human health, this situation incurs a 
worldwide increase in the cost of hospital care, including the use of new 
expensive drugs, increased costs for bacteriological analysis and prolonged 
hospitalization (5). 
2.3 Sources of resistance in the environment  
Concern over resistance was originally confined to acquisition of resistance by 
microorganisms which cause epidemic disease and was an issue only with 
respect to clinically isolated strains. However, in recent years, antibiotic 
resistant bacteria have been isolated from virtually every environment on earth. 
Antibiotic resistance is not only found in pathogenic bacteria but also in 
environmental organisms inhabiting terrestrial and aquatic habitats (60).  This 
came as a surprise to many clinicians, because resistance was found in regions 
never exposed to human impacts. Even as awareness of environmental 
resistance has increased, many investigators have continued to restrict their 
concern to only those pathogens that survive in the environment. It was 
believed that they posed a danger to humans only if the disease they caused 
involved resistance to antibiotics.  
 
The occurrence of resistant bacteria in nature may have originated from 
antibiotic producing organisms, as suggested by the evidence that in some 
cases the mechanisms and genes protecting these organisms from the 
antibiotics they produce are similar to those responsible for resistance in clinical 
isolates (60). However, higher numbers of resistant bacteria occur in polluted 
habitats compared with unpolluted habitats (7, 8), indicating that humans have 
contributed substantially to the increased proportion of resistant bacteria 
occurring in the environment.  
The main risk for public health is that resistance genes are transferred from 
environmental bacteria to human pathogens. The ability of resistant bacteria 
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and resistance genes to move from one ecosystem to another is documented 
by the various cases in which transmission of resistant bacteria has been 
demonstrated between animals and humans (9, 10).  
 
Non-pathogenic organisms serve as a source from which pathogens can 
acquire genes conferring resistance, and in turn, they can become resistant by 
acquiring genes from pathogens discharged into the environment, e.g. via 
sewage or agricultural runoff. Thus, dissemination of resistant bacteria is not 
only a problem of the resistant pathogens themselves, but also availability of 
resistance genes to pathogens via gene transfer. 
 
Although resistant organisms can be found naturally in the environment, most 
resistance is associated with man-made impacts of some type, either 
agricultural or direct human impact (61). Possible mechanisms by which 
humans enhance the spread of antibiotic resistance among environmental 
bacteria include the deliberate or accidental introduction of antibiotics, resistant 
bacteria and resistance genes into the environment. Antibiotics exert a selection 
in favor of resistant bacteria by killing or inhibiting growth of susceptible 
bacteria; resistant bacteria can adapt to environmental conditions and serve as 
vectors for the spread of antibiotic resistance; resistance genes can be taken up 
by indigenous bacteria and spread by mechanisms of genetic transfer (9, 10). 
 
Antibiotic use in humans can lead to resistance in the environment via 
discharge of domestic sewage, hospital wastewater, and/or industrial pollution. 
In addition to use in humans, antibiotics are added to animal feed to treat 








2.4 Human impacts 
Humans can have significant impact on the occurrence of antibiotic resistance 
in the environment. Antibiotic resistant organisms from the human 
gastrointestinal tract, as well as unabsorbed antibiotics, can enter the 
environment via sewage. Domestic wastewater, however, often has less effect 
than hospital wastewater, since, in the latter, heavy antibiotic concentrations 
increase the impact. 
 
Antibiotics consumed by humans can act to select for resistant organisms in the 
human gut. Both the resistant microorganisms and antibiotic residues are 
excreted, entering the sewage system. Although most people consider the 
environment to be generally safe from contamination with untreated sewage, 
breaches occur frequently where leakage or overflow into groundwater or 
natural waters occurs (62). Raw domestic sewage contains high numbers of 
bacteria, often including antibiotic resistant bacteria. One report showed that, in 
healthy people, 80.5% of fecal samples contained resistant organisms (63). 
Although VRE in the U.S. is associated with hospitals, in Europe, VRE is 
widespread in the community. See tables 2.1 and 2.2. 
 
Table (2.1): Low-level Vancomycin Resistant Enterococci from Domestic 
Wastewater (64, 65, 66) 
 







a strains were also resistant to erythromycin (100%) 
b strains were also resistant to erythromycin (26%) 









Table (2.2): High-level Vancomycin Resistant Enterococci from Hospital 
Wastewater (62, 67) 
 






In Czechoslovakia, a study comparing resistance in municipal wastewater to 
that of clinical isolates showed higher resistance rates in wastewater within the 
same species. Gentamicin resistance in E. coli was 13.9% and 30% for 
Klebsiella and Enterobacter strains (68). 
 
Although sewage treatment processes reduce the numbers of bacteria in 
wastewater, the effluent will still generally contain large numbers of both 
resistant and susceptible bacteria. Schwartz et al. (66) showed a decrease in 
VRE from 16% in untreated wastewater to 12.5% at the outlet. High numbers of 
resistant coliforms have also been found in treatment plant effluents (63) and 
rivers that receiving effluent from treatment plants have higher numbers of 
resistant organisms. Even as early as 1983, Bayne, Blankson and Thirkell (69) 
found a significant increase in resistance to tetracycline, erythromycin, 
streptomycin, ampicillin, and penicillin in enterococci, when comparing isolates 
downstream from a treatment plant to those upstream. Coliforms isolated from 
sites downstream of a treatment plant in the Tama river in Japan showed 
significant increases in resistance to ampicillin and tetracycline (70).  
 
In Spain, resistance in Aeromonas isolates increased from 50% upstream to 
90% downstream of a treatment plant effluent, and resistance in enteric bacteria 
increased from 30% to 50% (71). In Sweden in 2003, erythromycin resistant 
enterococci were isolated from 63% of received water samples and VRE were 
isolated from 3% (64).  
 
Due to heavy antibiotic use, hospital wastewater contains larger numbers of 
resistant organisms than domestic wastewater. In Florida, vancomycin resistant 
E. faecium were isolated, without enrichment, from hospital wastewater (62). 
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VRE were found in 35% of the hospital sewage samples in two Swedish studies 
(64, 65). Twenty-five percent of enterococci were vancomycin resistant in a 
German study of biofilms from hospital wastewater, and of these, many were 
multiply resistant (66). Reinthaler et al. (63) showed significantly higher 
percentages of E. coli in the inlet water of a treatment plant receiving hospital 
waste than two other treatment plants. A study of Acinetobacter showed that an 
increase in the prevalence of oxytetracycline resistance was correlated with 
hospital wastewater (72). 
 
Industrial pollution can also influence the incidence of antibiotic resistance, with 
pharmaceutical plants yielding a particularly strong effect. Until the 1970s, it 
was common for pharmaceutical plant waste to be disposed of in regular 
landfills, but drug residues leaching from these landfills were detected in nearby 
groundwater systems (73). Guardabassi et al. (72) found high levels of multiply 
resistant Acinetobacter in pharmaceutical plant effluents. Higher levels of 
antibiotic resistance have also been associated with heavy metals from 
industrial pollution. McArthur and Tuckfield (74) were able to show that antibiotic 
resistance was correlated with the heavy metal content of sediments 
downstream of a nuclear reactor complex. 
 
2.5 Spread of resistance 
Historically, researchers have assumed that the danger posed by resistant 
organisms in the environment would be minimal, since bacteria (especially 
pathogens) introduced to an environment were generally believed to survive 
only for a relatively short time. In the last 20 years, however, work by many 
investigators (75, 76,77, 78) has shown that many bacterial species can survive 
far longer than once thought, and that organisms such as Vibrio cholerae, long 
considered to have a reservoir only in humans, not only survive, but are actually 
autochthonous to aquatic environments (79, 80). This drastically increases the 
probability that humans will come into contact with resistant pathogens from 
runoff or sewage. Additionally, even resistant non-pathogens can have a large 
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impact on human health, serving as a source of resistance genes to indigenous 
organisms. 
 
2.5.1 Spread of antibiotic resistance in sewage 
Sewage is waste matter resulting from the discharge into the sewers of human 
excreta and wastewater originating from the community and its industries. 
Sewage contains a high content of both organic and inorganic matter, as well as 
high densities of living organisms, including pathogenic, commensal and 
environmental bacteria. This characteristic composition makes sewage a 
particularly suitable ecological niche for the growth and spread of antibiotic 
resistance. 
 
2.5.2 Antibiotic selective pressure 
The acquisition of antibiotic resistance genes is generally independent of the 
presence of antibiotics. However, the exposure of bacteria to antibiotics confers 
an ecological advantage to resistant strains on susceptible strains, allowing 
them to become predominant in the bacterial population. This situation is 
commonly termed as antibiotic selective pressure and can occur in either the 
host in vivo (e. g., human or animal body) as a consequence of chemotherapy 
or in the environment, for example when antibiotic residues are introduced in 
sewage (81). 
 
Residues of antibiotics administered to humans and animals reach the sewage 
systems in urine or feces, in the form of either parent compound or degraded 
metabolites depending on the pharmacology of the specific antibiotic. 
Furthermore, an unknown amount of antibiotics enter the sewers by waste 
derived from antibiotic production and disposal of a surplus of drugs. Indeed, 
various antibiotics have been found in municipal sewage, including 
fluoroquinolones, sulfonamides and erythromycin metabolites (81, 82). The 
antibiotic concentrations found in sewage vary between 1 and 100 µg per liter. 
Such concentrations are 100- to 1000 fold lower compared with those 
necessary to inhibit resistant bacteria, but are sufficient to affect susceptible 
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bacteria (16, 83). Therefore, the occurrence of such antibiotic concentrations in 
sewage has the potential to select for antibiotic resistance. 
 
The fate of antibiotics in sewage depends on their chemical properties.  
Lipophilic and non-readily degradable substances are likely to be retained in the 
sludge, whereas, hydrophilic substances may be able to pass through treatment 
plants and end up in the natural recipients receiving treated sewage (84). It also 
appears that the solubility in water of drug metabolites is generally higher 
compared with the parent compounds (84). Thus, it is likely that a large 
proportion of the antibiotic residues introduced into the sewage system can 
reach surface waters through municipal sewage effluents. 
 
2.5.3 Non-antibiotic selective pressure 
Among the multitude of substances occurring in sewage, there are some that 
have the potential to select for antibiotic resistance, even though they are not 
antibiotics. Heavy metals and biocides are two important groups of non-
antibiotic substances showing this property. Heavy metals are widespread in 
sewage as a consequence of industrial pollution. Biocides are introduced into 
sewage by hospitals, farms, slaughterhouses and food-processing 
establishments; where these agents are used for the disinfection of 
environments and utensils, or by the community, due to the presence of these 
agents in house-hold products, such as soaps and dish washing detergents 
(85). 
 
There are two possible ways by which heavy metals and biocides can select for 
antibiotic resistance. The genes encoding resistance to heavy metals and 
biocides can be located together with antibiotic resistance genes on either the 
same genetic structure (e.g. plasmid), or different genetic structures within the 
same bacterial strain. Alternatively, bacteria can have unspecific mechanisms of 
resistance to different substances, including heavy metals, biocides and 
antibiotics. In both cases, exposure to one substance results in the selection of 
bacterial strains  also able to resist the other substance (co-selection) (85). 
 32
Genes encoding resistance due to heavy metals and antibiotics often co-exist 
on plasmids (85). In addition, unspecific mechanisms conferring resistance to 
both heavy metals and antibiotics are known to exist in some bacterial species 
(e.g. active pump-efflux system encoded by the marA gene in E. coli). The co-
selective property of heavy metals is confirmed by the indirect evidence that 
bacteria isolated from heavy metal-polluted marine sediment are significantly 
more resistant to antibiotics compared with bacteria isolated from unpolluted 
sites (86). 
 
Although genes encoding resistance to biocides have been found on plasmids 
and integrons (87), these substances are more likely to select for antibiotic 
resistance by induction of unspecific mechanisms of multiple resistance. 
Laboratory experiments have shown that biocides such as triclosan and pine oil 
can select for resistance to different antibiotics when bacteria are exposed to 
low concentrations of biocide (88, 89). Accordingly, the co-selective effect of 
biocides for antibiotic resistance could be particularly marked when these 
substances are dispersed in the environment, because of dilution and formation 
of concentration gradients. 
 
2.5.4 Optimal conditions for horizontal gene transfer 
Sewage is a suitable habitat for the transfer of resistance genes across different 
groups of bacteria. In this habitat, environmental bacteria meet resistant 
bacteria selected by use of antibiotics in human and veterinary medicine. 
Consequently, resistance genes occurring in bacteria of human and animal 
origin can be transferred to environmental bacteria, contributing to the formation 
of an environmental pool of resistant bacteria and resistance genes. 
 
The high concentrations of bacteria, nutrients and suspended solids in sewage 
are all factors enhancing horizontal gene transfer (90, 91). High bacterial 
concentrations increase the chance that donor and recipient cells come in 
contact. Nutrients are more likely to have an indirect influence on the 
occurrence of gene transfer by increasing the concentration and the metabolic 
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activity of bacteria. Suspended solids provide ideal surfaces on which the 
various components contributing to the process of horizontal gene transfer 
(bacteria, free DNA and bacteriophages) are concentrated. 
 
Plasmids and transposons harboring antibiotic resistance genes are widespread 
in the bacterial flora of sewage (92, 93). Multiple-resistant bacteria isolated from 
sewage can transfer plasmid-mediated antibiotic resistance at high frequencies 
in the laboratory (94, 95). Experiments performed using membrane chambers 
immersed in sewage have shown that high frequencies of transfer may also 
occur under real conditions (96, 97).  
 
2.6 Antibiotic resistance in Gaza Strip 
The rate of antibiotic resistance is high in Gaza strip, this high rate of resistance 
is likely due, in part, to the selective pressure resulting from the uncontrolled, 
unwise and frequent administration of those drugs and by antimicrobial agent 
policy that permits an easy access of the Palestinian health centers to those 
agents. This is also associated with the relatively low cost of these antimicrobial 
agents (98). 
 
One study in Gaza strip showed decreased susceptibility to many antimicrobial 
drugs used for empiric treatment of infections, especially amoxicillin, 
cotrimoxazole, doxycycline and penicillin. Antimicrobial resistance among gram-
negative bacilli in this study was notable. E. coli resistance to amoxicillin was 
80.1%, 58.5% to cotrimoxazole, 9.1% to ciprofloxacin and 3.0% to the amikacin. 
The high resistance rates of E. coli may be due to the mechanisms that involve 
alternations in the outer membrane protein and in the antibiotic efflux system in 
the cell membrane. Concerning the antimicrobial susceptibility patterns among 
gram-positive isolates, the results show that vancomycin resistance of S. 
aureus and Enterococcus faecalis was 1.8% and 3.2%, respectively (98).  
Second study conducted on the southern area of the Gaza Strip to identify the 
microorganisms that cause "community-acquired" urinary tract infections, found 
high proportion of the isolates resistant to amoxicillin (73.6%), doxycycline 
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(68.6%) and trimethoprim-sulfamethoxazole (66.1%). A high percentage of 
multiple-drug resistance was also observed for the majority of the isolates (99). 
 
According to third study investigated urinary tract bacterial isolates in Gaza 
strip, High rates of resistance were found to amoxicillin (82.5%), followed by 
cotrimoxazole (64.4%) and doxycycline (63.1%) while the lowest resistance was 
to amikacin and ceftazidime (10.0%). The resistance rate to ciprofloxacin was 
15.0% (100). Whereas, in a previous study (2000) carried out in Gaza Strip, 
lower resistance to ciprofloxacin (4.1%) was reported (99). The widespread and 
more often the misuse of antimicrobial drugs in Gaza Strip have led to a general 
rise in the emergence of resistant bacteria, particularly to ciprofloxacin (100). 
 
Fourth study conducted in the Khan Younis hospital laboratory to evaluate 
susceptibility patterns in Pseudomonas aeruginosa causing nosocomial 
infections. The results demonstrated that most common resistance was to 
ampicillin, followed by cephalexin. The most effective antimicrobial agents were 
meropenem and amikacin, respectively. The highest resistance to ciprofloxacin 
was found among ICU and surgery sections (101). 
 
2.7 Antibiotic resistance in neighboring countries 
Not only Gaza that suffer from this increasing problem but also in other 
countries, "Israel" for instance as shown in a study conducted to compare  
susceptibility patterns of 8338 community urinary isolates collected during 1995 
with 6692 isolates from 1999. This study demonstrated that ampicillin, first 
generation cephalosporins and sulphamethoxazole/trimethoprim could no 
longer be considered first line drugs for empirical treatment of clinically evident 
urinary tract infection because of very high resistant rates. Ampicillin remained a 
good choice for urinary infections caused by enterococci, 98% of the strains 
being susceptible. It was found that 1.25% of the gram-negative uropathogens 
isolated during 1999 were extended spectrum beta-lactamase producers (102). 
 
Another study was executed in Israel on Methicillin-Resistant Staphylococcus 
aureus  showed that  hospital-acquired MRSA isolates were persistently highly 
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resistant to chloramphenicol (69% in 1988 and 100% in 1997 ), gentamicin 
(89% in 1988 to 94% in 1997), and ciprofloxacin (87% in 1988 to 96% in 1997). 
The resistance to clindamycin (62% in 1988 to 92% in 1997), fusidic acid (6% in 
1988 to 14% in 1997), and rifampicin (21% in 1988 to 76% in 1997) increased 
significantly. All isolates were sensitive to vancomycin (103). 
 
A third study also in Israel on Streptococcus pneumoniae showed that  that of 
the 437 isolates, 276 (63.4%) were antibiotic resistant and 156 (35%) were 
penicillin nonsusceptible (PNS). The isolates were mostly nonsusceptible to 
SXT (51%), penicillin (35%), and erythromycin (10%). Resistance to 
tetracycline, clindamycin, and chloramphenicol was found in 11, 5, and 2% of 
the isolates, respectively. Of the 154 isolates that were nonsusceptible to 
penicillin, 97 of 154 (63%) were intermediately susceptible and 37 of 154 (37%) 
were highly penicillin resistant. These two groups comprised 22 and 13% of all 
S. pneumoniae isolates, respectively (104).  
In Jordon a study on antibiotic sensitivity of Enterobacteriaceae isolated from 
patients with community acquired urinary tract infections demonstrated that high 
rates of resistance were found against ampicillin (95%), tetracycline (86%), 
carbenicillin (84%), trimethoprim/sulphamethoxazole (48%), and 
amoxicillin/clavulanic acid (45%). For the antibiotics tobramycin, aztreonam, 
ceftriaxone and gentamicin 7% of the isolates were resistant, while resistance 
varied from 9-18% for amikacin, ciprofloxacin, norfloxacin, nalidixic acid and 
cefuroxime (105). 
In Egypt a study on antimicrobial susceptibility of E. coli and Shigella spp. 
isolated from rural Egyptian pediatric populations with diarrhea between 1995 
and 2000, showed that the cumulative rates of resistance for E. coli and 
Shigella spp. were high (68.2% and 54.8% for ampicillin, 24.2% and 23.5% for 
ampicillin-sulbactam, 57.2% and 42.5% for trimethoprim-sulphamethoxazole, 
and 50.9% and 75.4% for tetracycline respectively). Non-enterotoxigenic E. coli 
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(NETEC) isolates had a consistently higher level of antimicrobial resistance 
than did enterotoxigenic E. coli (ETEC) isolates (106). 
Another study in Egypt which reviewed the antimicrobial susceptibility patterns 
of bloodstream isolates of Gram-positive cocci and Gram-negative bacilli in five 
hospitals in Cairo, Egypt, from 1999 to 2000. In addition, susceptibilities of non-
bloodstream isolates of Streptococcus pneumoniae and Enterococcus spp. 
were analyzed. High rates of resistance were found in most of the bacteria 
studied. Staphylococci were highly resistant to erythromycin, co-trimoxazole, 
clindamycin and doxycycline; all isolates were susceptible to vancomycin. 
Susceptibility of S. pneumoniae isolates to penicillin, ceftriaxone and 
fluoroquinolones was 63%, 84% and 82%, respectively. Vancomycin 
susceptibility of the enterococci was 96%; susceptibility to high-level gentamicin 
and streptomycin was 54% and 48%, respectively. Resistance to most relevant 
antimicrobials was commonplace among the Gram-negative bacilli; however, 
most remained susceptible to imipenem. The percentage of bloodstream 
isolates of Escherichia coli susceptible to common antimicrobial agents was as 
follows: ampicillin (6%), ampicillin–sulbactam (38%), co-trimoxazole (38%) and 
aminoglycosides (52%). The susceptibility of isolates of E. coli, Klebsiella and 
Enterobacter spp. to ceftazidime was 62%, 40% and 46%, respectively (107). 
2.8 Global problem of antibiotic resistance 
From the above studies we can easily conclude that antimicrobial resistance 
among bacterial pathogens is a global problem. No country on its own can 
isolate itself from resistant bacteria. Antibiotic resistance is a growing 
international problem affecting both current and future generations. Resistance 
that develops in one area of a country may easily spread nationwide. 
Globalization, with increased migration, trade and travel, has widened the range 
for infectious diseases.  A resistant strain of Streptococcus pneumoniae, first 
identified in Spain, was soon afterwards found in Argentina, Brazil, Chile, 
Taiwan, Malaysia, the USA, Mexico, the Philippines, the Republic of Korea, 
South Africa and Uruguay (108). Such examples underline the fact that no 
single country can protect itself from the threat of resistant bacteria as 
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pathogens are spreading across international, cultural and ethnic boundaries. 
Although the effects of antibiotic resistance are more documented in 
industrialized countries, there is a greater potential for harm in the developing 
world, where many of the second and third line therapies for drug-resistant 








3.1.1 Media and reagents 
Blood Agar Base, MacConkey Agar, Bile Esculin Azide Agar, M-Enterococcus 
Agar Base Modified, Pseudomonas Agar Base, HiCrome UTI Agar modified, 
Muller Hinton Agar, Brain Heart Infusion Broth, Triple Sugar Iron Agar 
(HiMedia). Oxidase reagent, antimicrobial susceptibility test HiDiscs 
Cartridges (HiMedia) and API 20 E (biomeroux). All media and reagents were 
prepared as recommended by the manufacturers. 
  
3.1.2 Equipment 
• Autoclave (Tutanuer) 
• Incubator 37°C  (Memmert) 
• Balance 
• Binocular microscope (OLYMPUS) 
• Sewage collection tool (Home made) 




3.2.1 Sampling sites selection and identification 
As part of the study, samples of sewage were collected from sewers and 
sewage treatment plants. Four different sites were selected for the study and 
from each site samples were collected from different locations. Table (3.1)  
and figure (3.1) illustrate the sampling sites and locations. 
Figure (3.2) illustrate the path that the wastewater take through its way to 
GWWTP on Gaza map. 






















Figure (3.1): A schematic presentation of the sampling locations 
  
3.2.1.1 Sampling sewers   
Samples of sewage were collected from three separate sewers receiving 
waste effluent from three different units in Al-Shifa hospital, and samples of 
sewage were collected from three separate sewers receiving waste effluent 
from three different buildings in Islamic University-Gaza. 
The selection of the sampling sites was restricted by the access to the sewer 
system for the collection of samples. Differences in the occurrence of resistant 
Location of sample collection at each site  Number of sample Sites 




L building sewer, M building sewer and Laboratories 
building sewer  
15 IUG 
From inlet and outlet  10 GWWTP 
About 20 meters from the point of sewage discharge in 
seawater See fig. (3.1)  
5 Seawater 
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Hospital Islamic University                 Exit 
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bacteria between these sites were used to evaluate the impact associated 
with the discharge of waste effluent. 
  
3.2.1.2 Sampling Gaza Wastewater treatment plant (GWWTP) 
Samples of raw sewage and treated sewage were collected from inlet and 













3.2.1.3 Sampling seawater 
Samples of seawater about 20 meters from the point of sewage discharge 
from  GWWTP in the  sea as shown in figure (3.5 & 3.6)  were collected, to 
see the  impact of sewage discharge in the sea on the  bacteria present in the 
sea. Samples were collected below the surface at the shoreline, using sterile 













3.2.2 Sample collection 
 
Fig. (3.5): Sewage from GWWTP 
discharged in seawater. 
 
Fig. (3.6): Front view of the wastewater 
discharge pipe 
  
Fig. (3.3): Process of sample collection 
from GWWTP inlet 
  
Fig. (3.4): Process of sample collection 
from GWWTP outlet 
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3.2.2.1 Sampling Frequency and Duration 
 
From each site the sample were collected five times. Samples collection 
lasted from Jul. 2005 to Sep. 2005.  
 
3.2.2.2 Sample Containers 
Five hundreds ml plastic bottles were used. The sample bottles were sterilized 
by autoclaving at 121 oC for 15 minutes. 
  
3.2.2.3 Preservation and Storage of Samples 
Samples were collected in sterile containers and stored on ice until analyzed 
as recommended by American Public Health Association Standard Methods 
for the Examination of Water and Wastewater (110). 
 
3.3 Sample Processing  
Loop full of each specimen was inoculated on blood agar, MacConkey agar,  
M-Enterococcus Agar, Pseudomonas Agar,  HiCrome UTI Agar plates and 
Brain heart infusion broth tubes using bacteriological loop  and incubated 
aerobically at 37°C for 24–48 hours.  Growing colonies were identified 
biochemically in a systematic way according to standard methods (111). 
  
All Gram-negative rods were identified by using API 20E strips. The initial 
characterization of enterococci was based on catalase reaction, hemolysis, 
and colony morphology. Further identification of enterococci was 
accomplished by the use of bile esculin test.  
 
It is important to note that some bacterial strains were isolated from the same 
sample more than once; the sensitivity test was done for this isolate, if the 





























































Each specimen was inoculated on 
the following media and 
incubated aerobically at 37°C for 
24–48 hours 
BHIB 
After 24 hr subcultures were 







API 20E   
  
API 20E   
Small red 
colonies 
S/C on Bile 
Esculin Azide Agar 
Enterococcus 
formed dark 















Each bacteria give 
specific color on this 
media 
E. coli pink 
to red  
Proteus mirabilis 
light brown  
Pseudomonas 
aeruginosa colorless  
Klebsiella 
pneumoniae 




Confirmed by biochemical tests 
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3.4 Antimicrobial susceptibility testing 
Bacterial susceptibility testing was done by the disk diffusion method 
according to Kirby-Bauer method (112) following the NCCLS assessment 
criteria (113). Bacterial inocula were prepared by suspending the freshly 
grown bacteria in 4-5 ml sterile BHIB and the turbidity was adjusted to that of 
a 0.5 McFarland standard. The inoculum suspension was spread in three 
directions on a Mueller Hinton agar plate surface with a sterile swab Filter 
paper disks containing designated amounts of the antimicrobial drugs 
obtained from commercial supply firms  (HiMedia). 
 
The antimicrobial disks tested for all isolates were: Amikacin 30µg, 
Amoxycillin 30µg, Aztreonam 30µg, Ceftazidime 30µg, Ceftizoxime 30µg, 
Cephoxitin 30µg, Chloramphenicol  30µg, Ciprofloxacin 30µg, Co-Trimoxazole 
23.75µg, Gentamicin  10µg, Imipenem 10µg , Nalidixic Acid 30µg , Piperacillin 
100µg, Tetracycline 30µg, Tobramycin 10µg, were tested against Gram 
negative bacteria. On the other hands, Streptomycin 10µg , Tetracycline 
30µg, Teicoplanin 30µg,Vancomycin 30µg,  Ampicillin 10µg, Erythromycin 
15µg,  were tested against Gram positive bacteria. . The plates were 
incubated aerobically at 37°C for 18-24 hours. .,Zone of inhibtion around 
antibiotic disks were recorded and using the chart provided by the 
antimicrobials manufacturer, results were interpreted as sensitive, 
intermediate or resistant. 
 
 
3.5 Analysis of data 
Data generated from the study was tabulated as excell files and uploaded to 
Statistical Package for Social Sciences (SPSS version 11). Crosstabulation of 









This study was conducted during the period from June to September, 2005, and 
attempted to isolate E. coli, Pseudomonas spp., Proteus spp., Klebsiella spp., 
and Enteroccocus spp. from wastewater sample for the purpose of studying the 
possible contribution of Al-Shifa hospital to the increasing problem of antibiotic 
resistance. Standard antimicrobial susceptibility test was performed for all 
isolates. 
 
A total of 45 wastewater samples were collected from 9 different sampling 
points. Each point was sampled 5 times with 2 weeks intervals.  Three sampling 
points at Al-Shifa hospital (burn unit sewer, ICU unit sewer and laboratory 
sewer), another three from Islamic University-Gaza (L building sewer, M 
building sewer and laboratory building sewer), two from the Gaza Wastewater 
Treatment Plant (Inlet and outlet of the plant) and one from the seawater near 
the GWWTP discharge point. From the 45 wastewater samples, 154 bacterial 
strains were isolated. The highest number of bacteria isolated from Al-Shifa 
hospital and accounted for 32.5% (50 isolates) of the isolated bacteria followed 
by sites from the Islamic University-Gaza, 29.9% (46), GWWTP, 26.6% (41) 
and seawater 11.0% (17), as illustrated in details in Table 4.1 and  in Figure 4.1.  
 
Table (4.1): Frequency of bacteria isolated from each sampling point 
Bacteria Site E. coli Pseudomonas Klebsiella Proteus Enterococcus Total 
1. Burn 6 6 - 1 5 18 
2. ICU 6 4 2 1 3 16 
3. Laboratory 3 7 2 - 4 16 
4. L Building 6 4 2 - 1 13 
5. M building 5 6 2 - 5 18 
6. Lab. U 5 5 2 - 3 15 
7. Inlet 5 7 1 3 7 21 
8. Outlet 7 7 3 1 2 20 
9. Sea 6 5 2 1 3 17 












Figure (4.1): Distribution of bacterial isolates by sampling site. 
 
The most frequently identified bacterium was Pseudomonas spp. (33.1%) 
followed by E. coli (30.5%), Enterococcus spp. (21.4%), Klebsiella spp. (10.4%) 















































Figure (4.2): Frequency of different bacterial isolate. 
 
The gram-negative isolates showed wide variation in their response to the 
tested antimicrobial drugs as shown in Table 4.2. High resistance rate to 
amoxicillin (43.1%), ceftizoxime (33.3%), nalidixic acid (72.5%), cephalexin 
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(90.2%), aztreonam (19.6%), and ceftazidime (13.7%) was observed among 
Pseudomonas spp. The highest resistance rate was for tetracycline (100.0%), 
amikacin (100.0%), chloramphenicol and co-Trimoxazole (71.4%) was exhibited 
by Proteus spp. For imipenem , there was no resistance at all. 
 
The resistance pattern for each bacterium varied according to the site from 
which the bacteria were isolated . For E. coli the highest resistance rate to 
tetracycline, amoxicillin, ciprofloxacin and chloramphenicol was for those 
isolated from the inlet of the GWWTP and were (66.7%), (66.7%), (66.7%) and 
(33.3%) respectively. For tobramycin, nalidixic acid, cephalexin, Co-
Trimoxazole, piperacillin, gentamicin and Ceftazidime the highest rate of 
resistance for E. coli which was isolated from the laboratory building of IUG and 
account for (40.0%), (40.0%), (80.0%), (80.0%), (80.0%), (40.0%) and (40.0%) 
respectively as shown in Table 4.3. 
 
With regard to Pseudomonas spp., the resistance rate is shown to be high for 
most antibiotics and reached 100.0% for nalidixic acid, cephalexin, Co-
Trimoxazole and chloramphenicol. The Pseudomonas spp. strains isolated from 
Al-Shifa hospital and sea were more resistant to antibiotics than Pseudomonas 
spp. isolated from other sites as shown in Table 4.4. 
 
The most resistant Klebsiella spp. isolate was that isolated from the laboratory 
building of the IUG. The highest resistance rate of Klebsiella was observed 
against piperacillin (100.0%) as shown in Table 4.5.  
 
Proteus spp. constituted the lowest number of the isolated bacteria and showed 
high rate of resistance to tetracycline, Co-Trimoxazole, piperacillin ciprofloxacin 
and chloramphenicol which account for (100.0%) as shown in Table 4.6. 
 
The only Gram-positive isolate was Enteroccocus spp. and showed the highest 
rate of resistance to streptomycin followed by vancomycin and erythromycine.   
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This high resistance rate observed for all Enterococcus spp. regardless of the 
isolation site as shown in Table 4.7. 
 
Table (4.7):  Percentage resistance of Enterococcus spp. isolated from different 
sites to antibiotics 
 A: Ampicillin, Te: Tecoplanin, S: Streptomycin, E: Erythromycin, Va: Vancomycin and T:  
Tetracycline 
 
In Vitro activities of 6 different antibiotics against the Enterococcus spp. is 
illustrated in Table 4.8 and Figure 4.3. The highest resistance rate was to 
streptomycin (91.0%). Also it was, 75.8%, 60.6%, 39.3%, 9.1% and 6.1%, to 
vancomycin, erythromycin, tetracycline, teicoplanin and ampicillin, respectively. 
The lowest resistance was to ampicillin (6.1%). 
 










Site No. of 
isolates 
A Te S E Va T 
Burn 5  0.0 0.0 100.0 60.0 80.0 60.0 
ICU 3  0.0 0.0 100.0 50.0 100.0 0.0 
Laboratory 4  0.0 28.2 85.7 100.0 85.7 57.1 
L building 1  33.3 0.0 100.0  33.3 100.0 33.3 
M building 5  0.0 0.0 100.0  100.0 0.0 0.0 
Lab. B 3 25.0 0.0 100.0 100.0 100.0 50.0 
Inlet 7  0.0 0.0  66.7 33.3 33.3 33.3 
Outlet 2  0.0 0.0 100.0 20.0 60.0 40.0 
Sea 3  0.0 33.3 66.7 33.3 66.7 0.0 
Antibiotics % Resistance % Intermediate % Sensitive 
Ampicillin 6.1 51.5 42.4 
Erythromycin 60.6 27.3 12.1 
Streptomycin 91.0 9.1 0.0 
Teicoplanin 9.1 12.1 78.8 
Tetracycline 39.3 21.2 39.3 




























































In Vitro activities of 15 different antibiotics against the gram-negative bacterial 
isolates is illustrated in Table 4.9.  A high resistance rate among gram-negative 
bacteria was observed against cephalexin (52.1%) followed by Co-Trimoxazole 
and tetracycline (41.3%), chloramphenicol (39.7%), nalidixic acid (36.4%) and 

































A high proportion of the isolated strains showed resistance to more than two 
drugs. The percent of bacteria that are not resistant to any antibiotics is low 
compared with these with multiple resistant pattern. The multiple drug 
resistance of the isolates is illustrated in Table 4.10.  Pseudomonas showed 













Resistance Intermediate Sensitive 
Amoxycillin  35.5 18.2 46.2 
Amikacin 8.3 19.8 71.9 
Aztreonam 13.2 34.7 52.1 
Cephalexin 52.1 38.0 9.9 
Co-Trimoxazole 41.3 9.1 49.6 
Chloramphenicol 39.7 4.1 56.2 
Ciprofloxacin 12.4 11.6 76.0 
Ceftazidime 8.3 8.3 83.5 
Ceftizoxime 14.0 16.5 69.4 
Gentamicin 10.7 8.3 81.0 
Imipenem 0.0 0.0 100.0 
Nalidixic Acid 36.4 12.4 51.2 
Piperacillin  28.9 28.1 43.0 
Tetracycline 41.3 26.4 32.2 
Tobramycin 11.6 7.4 81.0 
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No. % No. % No. % 
Not resistant 11 23.4 2 3.9 1 3.00 
To one antibiotic 10 21.3 2 3.9 3 9.1 
To two antibiotics 5 10.6 4 7.8 11 33.3 
To three antibiotics 6 12.8 8 15.7 9 27.3 
To four Antibiotics 6 12.8 8 15.7 8 24.2 






There is growing concern about bacterial resistance to antimicrobials. Almost 
since the beginning of the antibiotic era, bacterial resistance has been seen as 
the major obstacle to successful treatment (113). 
 
Antibiotic resistance has become a major clinical and public health problem 
within the lifetime of most people living today (6).  Confronted by increasing 
amounts of antibiotics over the past 60 years, bacteria have responded to the 
deluge with the propagation of progeny no longer susceptible to them. While it is 
clear that antibiotics are pivotal in the selection of bacterial resistance, the 
spread of resistance genes and of resistant bacteria also contributes to the 
problem. Selection of resistant forms can occur during or after antimicrobial 
treatment; antibiotic residues can be found in the environment for long periods 
of time after treatment. Besides antibiotics, there is the mounting use of other 
agents aimed at destroying bacteria, namely the surface antibacterial agents 
available now in many household products. These too enter the environment. 
The stage is thus set for an altered microbial ecology, not only in terms of 
resistant versus susceptible bacteria, but also in terms of the kinds of 
microorganisms surviving in the treated environment. The world currently face 
multiresistant infectious disease organisms that are difficult and, sometimes, 
impossible to treat successfully (6).  
 
Antibiotic-resistant bacteria (115,116,117,118) and antibiotics (119) are 
discharged in various amounts in the environment as a result of the increasing 
and often indiscriminate use of antibiotics in medical, veterinary, and agricultural 
practices. 
Resistant bacteria may be selected by antibiotic substances in hospital effluent, 
municipal sewage, aeration tanks, the anaerobic digestion process of STPs or in 
soil. Furthermore, resistant bacteria are excreted and discharged into sewage or 
soil and other environmental compartments. Resistant and even multi-resistant 
pathogenic bacteria have been detected in wastewater and STPs, as well as in 
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other environmental compartments (72,120,121) Furthermore, in arid regions, 
wastewater containing resistant bacteria and antibiotics is used for irrigation, 
and sewage sludge serves as a fertilizer. This allows resistant bacteria to enter 
the food chain directly. Concentrations below therapeutic levels may play a role 
in the selection of resistance and its genetic transfer in certain bacteria. 
Exposure of bacteria to sub-therapeutic antimicrobial concentrations is thought 
to increase the speed at which resistant strains of bacteria are selected. 
Resistance can be transferred to other bacteria living in other environments 
such as ground water or drinking water (122). 
 
This study was conducted to examine the possible contribution of wastewater 
effluent from different parts of Al-Shifa hospital on the prevalence of resistant 
bacteria in the recipient sewers in comparison with the contribution of 
wastewater effluent from   non-health institution (Islamic University-Gaza) on 
the prevalence of resistant bacteria, and to see the impact of wastewater 
effluent from GWWTP in the seawater. 
 
In this study, different aspects concerning the occurrence and fate of antibiotic 
resistant bacteria in sewage were investigated: 
• The rate of resistant bacteria in the recipient sewers at Al-Shifa Hospital. 
• The susceptibility pattern of bacteria isolated from wastewater effluent 
from IUG and GWWTP. 
• The impact of wastewater effluent from GWWTP on the prevalence of 
resistant bacteria in the recipient seawater. 
 
In the present study, 45 wastewater samples were collected from 9 different 
sampling points. Out of those 45 wastewater samples, 154 bacterial strains 
were isolated (Refer to table 4.1 and figure 4.1). The highest number of bacteria 
isolated from  Al-Shifa hospital and accounted for 32.5% (50 isolates) of the 
isolated bacteria followed by sites from the Islamic University-Gaza, 29.9% (46), 
GWWTP, 26.6% (41) and seawater 11.0% (17). The most frequently identified 
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bacterium was Pseudomonas spp. (33.1%) followed by E. coli (30.5%), 
Enterococcus spp. (21.4%), Klebsiella spp. (10.4%) and Proteus spp. 
 
In the present study, table 4.2 showed that, a high percentage of antibiotic 
resistance among gram-negative isolates. For this isolates, high resistance rate 
to amoxicillin, ceftizoxime, nalidixic acid, cephalexin,  aztreonam, and ceftazidim 
(43.1%), (33.3%), (72.5%), (90.2%), (19.6%) and (13.7%) respectively  was 
observed among Pseudomonas spp. The highest resistance rate for 
tetracycline, amikacin, chloramphenicol and co-Trimoxazole (100%), (100%) 
and (71.4%) respectively was exhibited by Proteus spp. For imipenem antibiotic 
there was no resistance at all, it is important to indicate that the use of 
imipenem antibiotic in our hospitals is very restricted for life threatening 
infections,  and for this reason there is no resistance at all to this antibiotic.  
 
For gram-positive isolate (Enterococcus spp.), the highest resistance rate was 
to streptomycin (91.0%). Also it was, 75.8%, 60.6%, 39.3%, 9.1% and 6.1%, to 
vancomycin, erythromycin, tetracycline, teicoplanin and ampicillin, respectively. 
The lowest resistance was to ampicillin (6.1%), referred to Table 4.8. 
 
From this study we observed that, the resistance rate against most antibiotics 
was high, particularly those isolated from wastewater samples which were 
collected from Al-Shifa hospitals, GWWTP, the laboratory building of IUG and 
from seawater. The resistance rate for tetracycline was high for most of the 
isolated bacteria, tetracycline resistance rates similar or higher than those found 
in this study have been reported (72, 115,116,118).  
 
Also the resistance rate for nalidixic acid (Quinolones) was high, previous 
studies have demonstrated that quinolone resistance was less than 25% among 
environmental isolates (72,115,123). The high resistance rate for nalidixic acid 
may be due to the fact quinolones antibiotics are excreted mostly as unchanged 
substances, and they are among the most persistent antibiotics in the 
environment  (119).  
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In this study the resistance rate washigh for chloramphenicol antibiotic for most 
of the isolates. In contrast, chloramphenicol resistance are rare in most studies 
(116,117,118), possibly as the result of the restricted use of this drug. 
 
In comparison with the levels of antibiotic resistance reported in the literature for 
clinical isolates , gram-negative isolates particularly E. coli and Pseudomonas 
spp. that isolated from sewage were generally more susceptible to antimicrobial 
agents. This result confirms the data, reported previously by other authors   
(124,125). Acinetobacter spp. from sewage were also more susceptible to 
antimicrobial agents (72). 
 
The resistance pattern for each bacterium varied according to the site from 
which the bacteria were isolated. For E. coli the highest resistance rate to 
tetracycline, amoxicillin, ciprofloxacin and chloramphenicol was for those 
isolated from the inlet of the GWWTP, the same result was reported in previous 
study and indicated that the highest resistance rates were found in E. coli 
strains of a sewage treatment plant which treats not only municipal sewage but 
also sewage from hospitals (63) and another study indicated that the 
percentages of E. coli resistance in raw sewage were significantly high (70) . 
For tobramycin, nalidixic acid, cephalexin, Co-Trimoxazole, piperacillin, 
gentamicin and ceftazidime the highest rate of resistance was for E. coli which 
was isolated from the laboratory building of IUG.  
 
With regard to Pseudomonas spp., the resistance rate is shown to be high for 
most antibiotics particularly for nalidixic acid, cephalexin, Co-Trimoxazole and 
chloramphenicol, high resistant rate for Pseudomonas spp. Isolated from clinical 
sources against the same antibiotics was also demonstrated in another study 
conducted in Gaza Strip hospitals (98). The Pseudomonas spp. isolated from 
Al-Shifa hospital and sea were more resistant to antibiotics than Pseudomonas 
spp. isolated from other sites as shown in table 4.4. Another author found a 
higher incidence of resistance in the bacteria isolated from remote uplant tarns 
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than those isolated from a polluted lake or sewage, with the highest value being 
observed for pseudomonas, which are naturally multiresistant organisms (126).  
 
The most resistance Klebsiella spp. isolates were those isolated from the 
laboratory building of the IUG. The highest resistance rate of Klebsiella was 
observed against piperacillin (100%).  
 
The high resistance rate found in samples collected from the laboratory building 
of IUG is likely due to heavy metals, biocides and various chemicals that are 
discharged in sewage of this building and these substances have the potential 
to select for antibiotic resistance (127).   
 
Enteroccocus spp. showed the highest rate of resistance to streptomycin 
followed by vancomycin and erythromycine. This high resistance rate observed 
for all Enterococcus spp. regardless of the isolation site, results from other 
study indicate that the majority of the vancomycin resistance enterococci (VRE) 
were resistant to at least two of the tested antimicrobial agents besides 
vancomycin (65), another study indicated that VRE and ERE isolates were 
detected in most of the wastewater (128).  
 
Concerning the antibiogram of all bacteria that were isolated from the seawater, 
the results of this study indicated that, the percentage of resistance to 
antibiotics is generally high. Similarities in antimicrobial resistance rates and 
pattern between seawater isolates and AL-Shifa as well as GWWTP isolates 
were found. This high resistant rate for bacteria that were isolated from 
seawater may be due to the fact that only few compounds were partially 
biodegraded in under test conditions in aquatic systems (16) and most were 
persistent.  And this result is consistent with those reported in another study and 
reported that, the river, which is contaminated by treated wastewater with many 
kinds of pollutants, is also contaminated with antibiotic resistant coliform group 
bacteria and E. coli (70). Similarly, another author have reported that, An 
increase of resistances was also observed in strains isolated from rivers 
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receiving urban discharge (117) or hospital and pharmaceutical plant 
wastewaters (72). 
 
 As shown by the results of this research, the resistant rate for bacteria that 
were isolated from the inlet of GWWTP was generally higher than the resistant 
rate for those that isolated from the outlet of the plant, but for some antibiotics 
the resistant rate was the same for both isolates, for some the resistance rate 
was higher in the outlet isolates, and this result is slightly different from what 
have been reported in another study which demonstrated that, the percentages 
of resistance in raw sewage were significantly higher than those in the river 
water and in the treated water and thus the percentages of resistant bacteria in 
the wastewater treatment plant were decreasing during the treatment process 
(70). But it is important to note that the GWWTP was overloaded during the 
period of our study and the plant was not properly working during this period.  
 
This study indicates a high percentage of multiple drug resistance for the 
majority of the isolated strains. And this result is consistent with that reported in 
another study done in Gaza Strip but the isolated bacteria were isolated from 
patient's samples and indicated a high percentage of multiple drug resistance 
(99) and in this study the author correlated this finding to many factors that may 
contribute to this alarming situation, including the use of antimicrobial agents as 
prophylactics in surgery, antibiotic use in animal feeds, under-dosing of 
antibiotics, the widespread use of broad spectrum antibiotics and the sale of 
antibiotics over the counter and self-treatment with antibiotics. In this study we 
can attribute this to the fact that, sewage contains a high content of both organic 
and inorganic matter, as well as high densities of living organisms, including 
pathogenic, commensal and environmental bacteria. This characteristic 
composition makes sewage particularly suitable ecological niche for the growth 
and spread of antibiotic resistance  (126).  
 
In general, we demonstrated that bacterial isolates from wastewater samples,   
Al-Shifa hospital and Laboratory building of IUG contained higher number of 
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antibiotic resistant bacteria than bacteria that were isolated from other sites.  
Accordingly, previous studies have shown that waste effluent from hospitals 
contain higher levels of antibiotic-resistant enteric bacteria than waste effluent 
from other sources. Hospital waste effluent could increase the numbers of 
resistant bacteria in the recipient sewer by both mechanisms of introduction and 
selection for resistant bacteria. (13,14, 15).  
 
This finding is likely due, in part, to the selective pressure resulting from the 
exposure of bacteria that present in sewage to antibiotics and non-antibiotics 
substances that have the potential to select for antibiotic resistance. The waste 
effluent from Al-Shifa hospital contain residues of antibiotics administrated to 
patients reach the sewage systems in urine or feces, in the form of either parent 
compound or degraded metabolites depending on the pharmacology of the 
specific antibiotic. Furthermore, unknown amount of antibiotics enter the sewers 
by waste derived from disposal of a surplus of drugs. This result is quite similar 
to that reported by another author, who has stated that, indeed, various 
antibiotics have been found in municipal sewage, including flouroquinolones, 
sulfonamides and erythromycin metabolites (81, 82). The antibiotic 
concentrations found in sewage vary between 1 and 100 μg per liter. Such 
concentrations are 100- to 1000 fold lower compared with those necessary to 
inhibit resistant bacteria, but are sufficient to affect susceptible bacteria (16, 83). 
Therefore, the occurrence of such antibiotic concentrations in sewage has the 












Conclusions and Recommendations 
 
Environmental pollution with bacteria of public health significance and the 
likelihood of this bacteria gaining access to the food chain are the most critical 
areas of concern. To our knowledge, this was the first study done in Gaza Strip 
demonstrating the impact of waste effluent from hospital on the occurrence of 
resistant bacteria in sewage. From the present investigation, we can conclude 
that the release of wastewater from the hospital under study was associated 
with an increase in the prevalence of antibiotic resistance. 
 
6.1 Conclusions 
1. A high percentage of antibiotic resistance was demonstrated among 
gram-negative and gram-positive isolates. 
 
2. The resistance pattern for each bacterium varied according to the site 
from which the bacteria were isolated 
  
3. The resistant rate was high for most bacteria that isolated from the 
laboratory building of IUG. 
 
4. Enteroccocus spp. showed highest rate of resistance to streptomycin 
followed by vancomycin and erythromycin. This high resistance rate 
observed for all Enterococcus spp. regardless of the isolation site 
 
5. Antibiogram of all bacteria that were isolated from seawater was similar 
to bacterial isolates from other sites particularly from Al-Shifa hospital 
and GWWTP. 
 
6. resistant rate for bacteria that isolated from the inlet of GWWTP is 
generally higher than the resistant rate for those that isolated from the 
outlet of the plant with some exceptions. 
 
7. This study indicated a high percentage of multiple drug resistance for the 
majority of the isolated strains. 
 
8. In general, we demonstrated that bacteria isolates from wastewater 
samples from Al-Shifa hospital and Laboratory building of IUG had higher 




9. These results indicate that waste effluents from hospitals are an 






One major public health concern is the spread of resistant bacteria into the 
environment and community which would complicate management and 
increase the mortality rate of infectious diseases. Considering the result of this 
study, the followings are recommended: 
 
1. Hospitals should adapt strict infection control measures to prevent 
nosocomial infections. 
 
2. Governmental actions to regulate the process of prescribing antimicrobial 
should be carefully planned and implemented. 
 
3. It is important to educate health professional on proper disposal of 
antimicrobials left over in order to minimize their presence in the 
environment. 
 
4. It is also recommended that hospitals should have a small scale 
treatment plant for their wastewater before discharged into the public 
sewers. 
 
5. It is also important to educate the public about the proper use of 
antimicrobials through seminars, publications and media. 
  
6. Protocols on antibiotic usage should be regularly reviewed by experts 
based on local antimicrobial profiles data collected from various hospitals 
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7. This study suggests the necessity for continued monitoring of multidrug 
resistance in hospital and the environments. 
 
8. There is a new trend of monitoring antimicrobial resistance in a particular 
area that utilizes fecal indicators as makers for the over all resistance 
situation. The existing monitoring programs depends totally on data 
obtained from clinical isolates. This new trend could be a good research 
area to be explored. 
 
9. As this study was conducted on a single hospital, further investigation is 
needed to assess the role of waste effluent from hospitals on selection 
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